To take the CE quiz, click here.
This quiz is open until August 2027.
Genna F. Atiee
DVM, DACVIM (SAIM)
Dr. Atiee is a graduate of Texas A&M University and completed an internship and residency in small animal internal medicine at North Carolina State University’s College of Veterinary Medicine. She is a diplomate of the American College of Veterinary Internal Medicine and is fellowship-trained in interventional radiology. Dr. Atiee is currently a clinical assistant professor at Texas A&M, with assignments to both the internal medicine and interventional radiology and endoscopy services. Her professional interests include vascular and urinary interventions and the management of chronic kidney disease and urinary tract infections.
Read Articles Written by Genna F. AtieeAudrey Cook
BVM&S, MSc VetEd, MRCVS, DACVIM (SAIM), DECVIM-CA, DABVP (Feline)
Dr. Audrey Cook is a graduate of the University of Edinburgh. She completed an internship at NCSU and a residency in internal medicine at UC Davis. She is a Diplomate of the American and European Colleges of Veterinary Internal Medicine, and is one of the few internists with additional board certification in Feline Practice. After a decade in private referral practice, Dr. Cook joined the faculty at Texas A&M College of Veterinary Medicine. She is currently Professor and Chief of the Internal Medicine Service. Her clinical interests include canine and feline endocrinology and gastroenterology.
Read Articles Written by Audrey Cook
Urinary incontinence can profoundly impact quality of life for dogs and their caretakers. This article provides an overview of the common causes of urinary incontinence and outlines a logical approach for evaluation and management of dogs with this condition.
Take-Home Points
- Urinary incontinence (UI) is a common condition in dogs and is particularly prevalent in older females.
- Most dogs with UI have a storage disorder, meaning that urine is not retained appropriately within the urinary bladder.
- Congenital defects such as ectopic ureter are the most common cause of UI in juveniles.
- Selection of an appropriate medical therapy requires differentiation of UI due to a storage disorder from UI due to a voiding disorder.
- Interventions—cystoscopic or surgical—may be necessary for the effective amelioration of some causes of UI.
- Prompt referral for specialized diagnostics or treatments, when indicated, is expected to improve long-term outcomes for affected patients.
Urinary incontinence (UI), defined as the passive and involuntary leakage of urine, must be differentiated from periuria (the conscious voiding of urine in inappropriate locations).1 In some instances, complications related to UI such as urinary tract infection (UTI) can cause confusion, and care must be taken to establish a reliable clinical picture. The prevalence of UI in dogs is unclear, although it is well established that spayed female dogs are predisposed.2-6 The severity is variable, with clinical signs ranging from an occasional damp spot on bedding to persistent dripping throughout the day and night. However, even low-grade UI can impact patient wellbeing and cause substantial distress to caretakers2,3,7; it is therefore important to promptly identify the cause and offer appropriate management options.
Normal Voiding
Control of urination is complex; it includes a storage phase during which the bladder relaxes as it slowly fills and a voiding phase in which urine is deliberately released.1 Considered simplistically, the bladder acts as a reservoir for urine and the urethra functions as a sphincter; normal voiding requires coordinated contraction of the former and relaxation of the latter and is controlled by both local reflexes and inputs from higher centers. In dogs with UI, these normal processes are disrupted by mechanical or functional disorders.
Differentiating storage disorders from voiding disorders relies on determination of the postvoid residual volume (PVRV; i.e., the amount of urine remaining in the bladder after voluntary
urination). This is routinely calculated using 2D ultrasonographic measurements of bladder size (BOX 1). A normal PVRV is defined as < 1 mL/kg, while a PVRV > 3 mL/kg indicates urine retention; intermediate values are regarded as inconclusive.1 It can be helpful to determine PVRV immediately after a routine walk with the owner, as (in the authors’ experience) the stress of being in the clinic and observed by strangers may inhibit normal voiding behaviors.
- Postvoid residual volume (PVRV) = Length (a) × height (b) × width (c) × 0.52 / weight (kg)
- Maximal dimensions (in cm) should be used for each measurement (FIGURE A AND B).
- If the bladder is too large to be effectively captured in the image, dimensions can be approximated.
- For the patient shown in FIGURES A AND B, weighing 26.5 kg (58.4 lb), the estimated PVRV is (10.5 × 6.8 × 10.8 × 0.52) / 26.5 = 15.1 mL/kg.
Storage Disorders
Dogs with storage disorders have a PVRV < 1 mL/kg but are unable to retain urine reliably within the urinary bladder. Causes may be divided into non-neurogenic and neurogenic, with the former being most likely (FIGURE 1).1,2,5
Common non-neurogenic conditions include urethral sphincter mechanism incompetence (USMI) and congenital issues such as ectopic ureter. UTI also falls in this category, although affected dogs often have a concurrent contributory disorder. Less common considerations include pelvic bladder/short urethra, idiopathic detrusor instability, bladder fibrosis, and fistulae (ureterovaginal, urethrovaginal, urethrorectal). Depending on the underlying cause, dogs with non-neurogenic storage disorders may also consciously urinate normal volumes in appropriate locations.
Neurogenic conditions include problems affecting the sacrocaudal spinal cord or cauda equina, such as intervertebral disk herniation, trauma, and neoplasia.8
Urethral Sphincter Mechanism Incompetence
Dogs with USMI usually void small urine puddles while resting but are continent when active and engaged. Establishing a diagnosis of USMI requires exclusion of other likely possibilities. However, as this condition is the most common cause of UI in ovariectomized middle-aged female dogs, it is reasonable to make a presumptive diagnosis in these patients and assess the response to therapy (TABLE 1) before considering more advanced diagnostics (CASEÂ EXAMPLE).
| Table 1Â Drugs Routinely Used in the Management of Canine Urinary Incontinence | ||||
|---|---|---|---|---|
| Name | Dose | Drug Class and Mechanism of Action |
Indication | Comments |
| Acepromazine | 0.5–2.2 mg/kg PO q6–8h | Phenothiazine derivative; skeletal muscle relaxant |
Functional outflow obstruction | Adverse effects include sedation and hypotension. |
| Alprazolam | 0.02–0.1 mg/kg PO q12h | Benzodiazepine; skeletal muscle relaxant |
Functional outflow obstruction | Schedule IV controlled substance. Adverse effects include sedation and polyphagia. |
| Bethanechol | 2.5–25 mg/dog PO q8–24h | Muscarinic cholinergic agonist; stimulates detrusor contraction | Detrusor atony | Adverse effects include salivation and diarrhea. |
| Dantrolene sodium | 0.3–0.9 mg/kg PO q8h | Postsynaptic muscle relaxant; skeletal muscle relaxant | Functional outflow obstruction | Adverse effects include sedation, weakness, and hepatotoxicity. |
| Diazepam | 0.02–0.25 mg/kg PO q8h | Benzodiazepine; skeletal muscle relaxant | Functional outflow obstruction | Schedule IV controlled substance. Adverse effects include sedation. Give 30 minutes before walking. |
| Diethylstilbestrol | 0.1–1.0 mg PO q24h × 5 days, then weekly or as needed | Estrogen; increased sphincter responsiveness to norepinephrine, also inhibits gonadotropin-releasing hormone production | USMI (females) | Only (unapproved) compounded products available in the United States. Adverse effects include mammary and vulval swelling; myelosuppression may occur with incautious dosing. |
| Estriol | 2 mg PO q24h × 14 days, then reduce to 1 mg PO q24 | Estrogen; increased sphincter responsiveness to norepinephrine, also inhibits gonadotropin-releasing hormone production | USMI (females) | Some dogs can be maintained on every-other-day dosing. Adverse effects include mammary and vulval enlargement. |
| Lorazepam | 0.02–0.2 mg/kg PO q8–12h | Benzodiazepine; skeletal muscle relaxant | Functional outflow obstruction | Schedule IV controlled substance. Adverse effects include sedation and behavioral changes. |
| Methyltestosterone | 0.5 mg/kg PO q24h | Androgen; actual mechanism unclear | USMI (males) | Only (unapproved) compounded products available. Prolonged use is not advisable; patient with a positive response should be transitioned to testosterone cypionate. |
| Oxybutynin | 0.2–0.3 mg/kg PO q8–12h | Antimuscarinic and antispasmodic; reduces frequency of bladder contractions through parasympathetic blockade | Detrusor instability | Adverse effects include urine retention and hypersalivation. |
| Phenoxybenzamine | 0.5 mg/kg PO q24h or 0.25 mg/kg PO q12h |
α-Adrenergic antagonist; smooth muscle stimulant | Functional outflow obstruction | Adverse effects include hypotension and weakness. |
| Phenylpropanolamine | 2 mg/kg PO q8–12h or 2-4 mg/kg PO q24h extended-release formulation |
α-Adrenergic agonist; smooth muscle stimulant | USMI | Adverse effects include hypertension and restlessness. |
| Prazosin | 0.5–3 mg PO q8–12h | α-Adrenergic antagonist; smooth muscle stimulant | Functional outflow obstruction | Adverse effects include hypotension and weakness. |
| Tamsulosin hydrochloride | 0.4–0.8 mg/dog PO q24h | α-Adrenergic antagonist; smooth muscle stimulant | Functional outflow obstruction | Adverse effects include hypotension and weakness. Dose may be cautiously increased to 3 times a day if necessary. |
| Testosterone cypionate | 2.2 mg/kg IM q4–8 weeks | Androgen; actual mechanism unclear | USMI (males) | Only (unapproved) compounded products available in the United States. Adverse effects include aggression and prostatic hyperplasia. |
| USMI = urethral sphincter mechanism incompetence | ||||
The authors routinely prescribe estriol initially as this is usually well tolerated.2,9,10 Phenylpropanolamine can be added to the treatment plan if continence is not achieved within 3 to 4 weeks.11-13 Refractory cases may benefit from cystoscopic urethral bulking; this procedure requires general anesthesia but routinely provides > 9 months of improved continence.1,14,15 USMI in male dogs should be initially treated with phenylpropanolamine; androgens may be considered if this drug is not adequately effective.16 A permanent artificial urethral sphincter is an option for both male and female dogs in which standard therapy fails. These devices substantially improve continence in most dogs; however, significant complications such as urethral stricture have been reported in up to 30% of patients.17-19
A 5-year-old female spayed Doberman pinscher presented for additional management of urinary incontinence (UI). The owners reported that they first noticed small (hand-sized) wet spots on the dog’s bedding about 4 months earlier. These were initially uncommon but became an every-other-day or daily occurrence. Leakage only seemed to occur when the dog was resting. There were no other changes in urinary habits, and the dog continued to void appropriately outside 4 to 5 times a day. This dog was spayed at 6 months of age, prior to her first heat, and was otherwise well. On initial evaluation by her primary care veterinarian approximately 3 months after UI was first noted, the dog’s physical examination was unremarkable. A urine sample collected via cystocentesis had a specific gravity of 1.038 and pH of 6.5, with an unremarkable sediment examination. Based on these findings, the dog was presumptively diagnosed with urethral sphincter mechanism incompetence (USMI) and started on extended-release phenylpropanolamine at 2.1 mg/kg PO q24h. The owners noted some improvement in continence after 2 weeks but still routinely found wet spots on the bedding. Estriol was subsequently started at 2 mg PO q24h for 14 days, then 1 mg PO q24h, but appeared to provide minimal benefit and was subsequently discontinued. The dog was referred to an internist for further evaluation.
Diagnostic Findings
The dog’s physical examination was unremarkable. There was no evidence of urine scald or perivulvular dermatitis. Results of a CBC and serum biochemical profile were unremarkable. Transabdominal ultrasonography showed normal kidneys and a midsized urinary bladder. No masses or stones were noted, and both ureteral openings appeared to be within the trigone. The dog was observed to urinate normally when outside and had a postvoid residual volume of 0.4 mL/kg. Findings on routine urinalysis were similar to those reported before, and a quantified urine culture was negative. The dog was anesthetized a few days later for cystourethroscopy performed with a 2.7-mm 30° rigid pediatric cystoscope with the patient in dorsal recumbency. The vestibule was unremarkable, but a vestibulovaginal septal remnant was noted spanning the vaginal opening and was ablated with a diode laser (FIGURE A).
The urethral walls were smooth and pink; urethral length was somewhat shorter than expected at 7 cm. The trigone was clearly defined and was easily traversed with the cystoscope. The urinary bladder wall was unremarkable, with no stones or masses. Both ureteral openings were identified and appeared normal. A urethral bulking agent containing cross-linked porcine gelatin (VetFoam; BioChange, biochange.life) was injected at 3 sites within the proximal urethra, approximately 1 cm caudal to the trigone. About 1.3 mL of bulking agent was injected at each site, with the 3 blebs positioned at regular intervals around the circumference of the urethra (FIGURE B). The dog was discharged with a 3-day course of carprofen (2 mg/kg PO q12h), and the owner was instructed to discontinue phenylpropanolamine. Four weeks postprocedure, the dog was fully continent and able to void comfortably.
Discussion
This dog’s history is very consistent with USMI. This case is likely due to a combination of diminished urethral tone secondary to ovariohysterectomy and a somewhat short urethra. Although many dogs respond well to medical management, some experience adverse effects or have limited improvement. Urethral bulking agents are excellent options for female dogs with refractory USMI, with response rates greater than 90% reported.1 Patients should be screened for UTI prior to administration of a bulking agent. As urethral bulking agents are delivered through a rigid scope, this treatment option is not routinely performed in males. However, bulking agents can be injected into the distal urethra with a rigid scope in large males or via a perineal approach in smaller individuals. Vestibulovaginal septal remnants may be incidental and unrelated to lower urinary tract disease, but they sometimes distort the urethral papilla and have been associated with recurrent urinary tract infection.2 The authors routinely ablate these during cystoscopic examinations in case they are contributing to clinical problems. The urethral bulking agent used in this case is expected to slowly dissipate within a year, at which time the incontinence may recur. In some patients, restarting phenylpropanolamine may be sufficient to achieve continence for a few more months. However, owners should be counseled that the procedure will likely need to be repeated for long-term maintenance of continence.
References
- Chen H, Shipov A, Segev G. Evaluation of cross-linked gelatin as a bulking agent for the management of urinary sphincter mechanism incompetence in female dogs. J Vet Intern Med. 2020;34(5):1914-1919. doi:10.1111/jvim.15857
- Burdick S, Berent AC, Weisse C, Langston C. Endoscopic-guided laser ablation of vestibulovaginal septal remnants in dogs: 36 cases (2007–2011). JAVMA. 2014;244(8):944-949. doi:10.2460/javma.244.8.944
Ectopic Ureter
This condition can be unilateral or bilateral and is the primary cause of incontinence in juvenile dogs.1 Affected animals usually drip urine continuously and often get severe urine scald. The abnormal ureteral opening(s) can be repositioned within the bladder through cystoscopic laser ablation or surgical reimplantation.20-22 The latter option should be reserved for dogs with extramural ectopia; cystoscopic laser ablation is the superior option for dogs with intramural (tunnelling) ectopic ureters as complications are rare and the recovery time is brief. Unfortunately, some dogs with ectopic ureter remain incontinent after correction; this is often due to a concurrent short urethra and may improve with phenylpropanolamine.21,22
Idiopathic Detrusor Instability
This condition—also known as hyperactive bladder—is characterized by involuntary bladder contractions despite minimal filling; affected dogs exhibit urinary urgency or dribble urine after voiding.1,3 Definitive diagnosis requires cystometry (see under IMAGING below), but it is reasonable to assess the response to drugs (TABLE 1) such as oxybutynin, an anticholinergic antispasmodic, if the clinical picture is consistent with this diagnosis and conditions such as UTI or urinary tract neoplasia have been reliably excluded.
Voiding Disorders
Dogs with UI due to a voiding disorder are unable to effectively empty the bladder, and PVRV is > 3 mL/kg.1 This condition is sometimes referred to as overflow incontinence, as urine leaks out when the storage capacity of the bladder is exceeded; this is routinely noted when the dog is resting. These dogs may attempt to urinate but only pass dribbles or short spurts of urine.23 In some cases, a small amount of urine may be forcibly ejected from the bladder when deliberate efforts to void are abandoned.
Patients with voiding disorders may again be broadly categorized as having non-neurogenic or neurogenic disorders (FIGURE 1).1 Non-neurogenic issues are subcategorized as mechanical or functional; mechanical causes include urolithiasis, urinary tract neoplasia, urethral stricture, prostatic disease, bladder displacement, and extramural compression. Functional disorders include bladder atony or fibrosis and idiopathic functional outflow obstruction. Common neurogenic causes of voiding disorders include those affecting the T3 to L3 and S1 to S3 spinal regions, such as intervertebral disk herniation, ischemic myelopathy, and degenerative lumbosacral stenosis.24,25 Prognosis and treatment will depend on the underlying cause.
Bladder Displacement
Conditions such as perineal hernia can compromise urine voiding.26,27 Affected dogs are usually intact middle-aged males, and concurrent prostatomegaly may play a role. On digital rectal examination, there is often an obvious weakness within the pelvic canal; in severe cases, a bulge may be visible on either side of the anus. Urethral kinking with caudal displacement of the urinary bladder may occur in dogs of any sexual status and can cause severe compromise to micturition.28 As the affected dog postures to urinate, the bladder moves caudally, and the urethra becomes compressed and occluded. Signs can be intermittent but tend to be more pronounced when the bladder is fully distended. This condition may be diagnosed using contrast cystourethrography and is addressed by surgically securing the cranial aspect of the bladder to the ventrolateral abdominal wall.
Idiopathic Functional Outflow Obstruction
This condition was traditionally referred to as detrusor–urethral dyssynergia or reflex dyssynergia and is due to failure of the bladder to contract and/or failure of the urethra to relax.1 Affected patients are usually large-breed, middle-aged males, and clinical signs range from a narrowed and erratic urine stream to complete inability to void.29-31 Signs can wax and wane, and treatment may be delayed if owners fail to grasp the significance of changing urinary patterns. These dogs are particularly prone to secondary bladder atony, as long periods of incomplete emptying slowly stretch the wall and damage the connections between the detrusor fibers.
Treatments focus initially on urethral relaxation (TABLE 1), with α-adrenergic blockers such as prazosin, tamsulosin, or phenoxybenzamine. Skeletal muscle relaxants such as dantrolene sodium, acepromazine, or a benzodiazepine may also be useful, particularly in males, as these agents reduce tone in the extensive urethralis muscle.1 Concurrent detrusor atony may be subsequently addressed with bethanechol; if indicated, the authors introduce this drug 2 to 3 days after starting urethral relaxants.
Patient Evaluation
The first step in the evaluation of a patient with UI is to collect a detailed history, including duration of clinical signs, pattern(s) of incontinence, voiding behaviors, and response(s) to previous therapy. Patient signalment should be considered; UI in puppies is usually due to anatomic defects such as ectopic ureter, whereas UI in older dogs is more likely to be USMI or related to mechanical or functional obstruction.
On physical examination, careful attention should be paid to the appearance of the external genitalia and surrounding skin. Are the tissues inflamed or urine scalded? A digital rectal examination should be performed in all dogs, as abnormalities of the urethra or prostate may be noted. In older intact males, the structural integrity of the pelvic diaphragm should be carefully assessed. Urinary bladder size and tone should be noted, along with any signs of discomfort. A full neurologic examination should also be performed, including assessment of anal tone. It is also very helpful to observe the dog’s behavior during micturition, including ability to effectively posture, and the strength of the urine stream. If necessary, the dog may need to be placed off-leash in a secured area to facilitate voiding. The PVRV should then be established to narrow the list of possible causes of UI.
Diagnostic Testing
Findings on routine urinalysis should be carefully evaluated. Pyuria and bacteriuria indicate UTI; this is most likely to be secondary to UI rather than the cause, although cystitis can exacerbate leakage or trigger urge incontinence in dogs with mild USMI. A quantified urine culture should be performed if UTI is suspected and results used to guide therapy. Abnormal transitional epithelial cells or evidence of squamous metaplasia suggest obstructive conditions and indicate the need for imaging to evaluate urinary tract and prostatic anatomy. Poorly concentrated urine is not a reason for UI per se but will certainly affect the magnitude and frequency of leakage.
Results of a CBC and serum biochemical profile should be evaluated. Although these tests are unlikely to provide direct insight into the cause of UI, concurrent issues such as chronic kidney disease or endocrinopathy may exacerbate UI by driving polyuria and should be addressed as appropriate.
Imaging
Plain abdominal radiography can provide insight into the size and position of the kidneys, urinary bladder, and prostate (FIGURE 2A) and can reliably identify radiopaque uroliths. Readily apparent stones are usually calcium oxalate or magnesium ammonium phosphate (struvite); urate stones may sometimes be noted with high-quality imaging.32,33 In males, the perineal and penile urethra are best evaluated with the back legs pulled cranially (FIGUREÂ 2B). Compressing the bladder with a paddle may facilitate the detection of small cystoliths (FIGUREÂ 2C AND 2D).
Transabdominal ultrasonography allows for detailed evaluation of the kidneys, ureters, urinary bladder, proximal urethra, and prostate, as well as routine identification of masses, cysts, stones, and extraluminal compressive lesions. Although ureteral jets may be visualized using color Doppler ultrasonography, this imaging modality may not reliably identify an ectopic ureter and most experts prefer to rely on cystoscopy to establish or refute this diagnosis.1,34
Contrast radiographic studies can be performed using standard radiography, fluoroscopy, or computed tomography. As a general rule, patients should be deeply sedated or fully anesthetized for these studies to ensure adequate image collection and minimize risk to personnel. The most appropriate modality will depend on the likely causes of UI in a particular patient. Retrograde positive-contrast cystourethrography is often the best choice for patients with signs suggestive of mechanical urethral obstruction; fluoroscopic contrast studies are particularly useful in dogs with fistulae or those with dynamic mechanical obstructions due to caudal displacement of the bladder.1,28 Computed tomography with intravenous contrast administration allows more detailed evaluation of the anatomy without the hindrance of anatomic superimposition. This modality has superior diagnostic reliability for dogs with ectopic ureter than ultrasonography or traditional retrograde contrast studies but is still less sensitive than cystoscopy.35
Cystourethroscopy, direct endoscopic visualization of the urethra and bladder, is highly informative in many instances, and is the most reliable way to identify or exclude urolithiasis, stricture, neoplasia, and ureteral ectopia (FIGURE 3). General anesthesia is required for cystourethroscopy, and practitioners must be adequately trained. Rigid cystoscopy is routinely performed in females, whereas a flexible scope is required for males. Patient size must be considered, as the urethra must comfortably accommodate the scope. In males, it is prudent to pass an appropriately sized red-rubber catheter before scheduling cystourethroscopy to be sure that the scope will be able to traverse the distal urethra. If necessary, a minimally invasive perineal approach may be used in males to allow access to the pelvic and prostatic urethra with a rigid scope.36
Urodynamic studies such as cystometry and urethral pressure profiling are available at some referral centers and can provide specific information regarding lower urinary tract function.1,37 However, specialized equipment and standardized sedation/anesthesia protocols are necessary, and most clinicians feel that the benefits of performing these studies are limited. Cystometry determines the amount of fluid required to trigger involuntary detrusor contraction and is needed to confirm a diagnosis of detrusor instability or bladder fibrosis.1 Urethral pressure profiling assesses the tone of the urethra and can confirm USMI.1
Summary
It is essential to establish a diagnosis in a dog with UI so that appropriate tests and treatments are provided in a timely manner. Initial differentials are influenced by signalment, history, and urine characteristics and should be combined with determination of PVRV. Referral should be recommended for challenging or refractory cases.
References
1. Kendall A, Byron JK, Westropp JL, et al. ACVIM consensus statement on diagnosis and management of urinary incontinence in dogs. J Vet Intern Med. 2024;38(2):878-903. doi:10.1111/jvim.16975
2. Falceto MV, Caccamo R, Garrido AM, et al. An international survey on canine urinary incontinence: case frequency, diagnosis, treatment and follow-up. Front Vet Sci. 2024;11:1360288. doi:10.3389/fvets.2024.1360288
3. Acierno MJ, Labato MA. Canine Incontinence. Vet Clin North Am Small Anim Pract. 2019;49(2):125-140. doi:10.1016/j.cvsm.2018.11.003
4. Hall JL, Owen L, Riddell A, Church DB, Brodbelt DC, O’Neill DG. Urinary incontinence in male dogs under primary veterinary care in England: prevalence and risk factors. J Small Anim Pract. 2019;60(2):86-95. doi:10.1111/jsap.12951
5. Pegram C, O’Neill DG, Church DB, Hall J, Owen L, Brodbelt DC. Spaying and urinary incontinence in bitches under UK primary veterinary care: a case–control study. J Small Anim Pract. 2019;60(7):395-403. doi:10.1111/jsap.13014
6. Byron JK, Taylor KH, Phillips GS, Stahl MS. Urethral sphincter mechanism incompetence in 163 neutered female dogs: diagnosis, treatment, and relationship of weight and age at neuter to development of disease. J Vet Intern Med. 2017;31(2):442-448. doi:10.1111/jvim.14678
7. Salman MD, Hutchison J, Ruch-Gallie R, et al. Behavioral reasons for relinquishment of dogs and cats to 12 shelters. J Appl Anim Welf Sci. 2000;3(2):93-106. https://doi.org/10.1207/S15327604JAWS0302_2
8. Pfund R, Forward AK, Fentem R, Nagendran A, Fraser AR, Crawford AH. Postoperative outcome of ambulatory dogs with intervertebral disc extrusion causing incontinence and/or tail dysfunction: 18 cases (2010-2020). J Small Anim Pract. 2022;63(7):550-558. doi:10.1111/jsap.13497
9. Mathews KD, Hardy B, Johnson EG, Westropp JL. Ultrasonographic evaluation of uterine stump size in ovariohysterectomized dogs receiving estriol compared to control dogs. Top Companion Anim Med. 2020;38:100370. doi:10.1016/j.tcam.2019.100370
10. Applegate R, Olin S, Sabatino B. Urethral sphincter mechanism incompetence in dogs: an update. JAAHA. 2018;54(1):22-29. doi:10.5326/JAAHA-MS-6524
11. Byron JK, March PA, Chew DJ, DiBartola SP. Effect of phenylpropanolamine and pseudoephedrine on the urethral pressure profile and continence scores of incontinent female dogs. J Vet Intern Med. 2007;21(1):47-53. https://doi.org/10.1111/j.1939-1676.2007.tb02927.x
12. Scott L, Leddy M, Bernay F, Davot JL. Evaluation of phenylpropanolamine in the treatment of urethral sphincter mechanism incompetence in the bitch. J Small Anim Pract. 2002;43(11):493-496. doi:10.1111/j.1748-5827.2002.tb00020.x
13. Claeys S, Rustichelli F, Noël S, Hamaide A. Clinical evaluation of a single daily dose of phenylpropanolamine in the treatment of urethral sphincter mechanism incompetence in the bitch. Can Vet J. 2011;52(5):501-505.
14. Chen H, Shipov A, Segev G. Evaluation of cross-linked gelatin as a bulking agent for the management of urinary sphincter mechanism incompetence in female dogs. J Vet Intern Med. 2020;34(5):1914-1919. doi:10.1111/jvim.15857
15. Byron JK. Injectable bulking agents for treatment of urinary incontinence. In: Weisse C, Berent A, eds. Veterinary Image-Guided Interventions. John Wiley & Sons; 2015:410-414. Accessed January 21, 2025. https://doi.org/10.1002/9781118910924.ch38
16. Palerme JS, Mazepa A, Hutchins RG, Ziglioli V, Vaden SL. Clinical response and side effects associated with testosterone cypionate for urinary incontinence in male dogs. JAAHA. 2017;53(5):285-290. doi:10.5326/JAAHA-MS-6588
17. Currao RL, Berent AC, Weisse C, Fox P. Use of a percutaneously controlled urethral hydraulic occluder for treatment of refractory urinary incontinence in 18 female dogs. Vet Surg. 2013;42(4):440-447. doi:10.1111/j.1532-950X.2012.01040.x
18. Bohlen M, Nickel R. Artificial urethral sphincter in male dogs with urethral sphincter mechanism incompetence: 19 cases (2010–2017). J Small Anim Pract. 2022;63(5):397-402. doi:10.1111/jsap.13473
19. Rose SA, Adin CA, Ellison GW, Sereda CW, Archer LL. Long-term efficacy of a percutaneously adjustable hydraulic urethral sphincter for treatment of urinary incontinence in four dogs. Vet Surg. 2009;38(6):747-753. doi:10.1111/j.1532-950X.2009.00560.x
20. Berent AC, Weisse C, Mayhew PD, Todd K, Wright M, Bagley D. Evaluation of cystoscopic-guided laser ablation of intramural ectopic ureters in female dogs. JAVMA. 2012;240(6):716-725. doi:10.2460/javma.240.6.716
21. Noël SM, Claeys A, Hamaide AJ. Surgical management of ectopic ureters in dogs: Clinical outcome and prognostic factors for long-term continence. Vet Surg. 2017:46(5):631-641. doi/:10.1111/vsu.12654
22. Hoey CSFK, Friend E, Meakin LB, Chanoit GP. Long-term outcome of female dogs treated for intramural ectopic ureters with cystoscopic-guided laser ablation. Vet Surg. 2021;50(7):1449-1462. doi:10.1111/vsu.13702
23. Mathews K, Toedebusch C, Palm C, Kendall A, Westropp JL. Idiopathic functional urinary outflow tract obstruction in dogs, a retrospective case series (2010-2021): 31 cases. J Vet Intern Med. 2023;37(6):2211-2218. doi:10.1111/jvim.16843
24. Granger N, Olby NJ, Nout-Lomas YS. Bladder and bowel management in dogs with spinal cord injury. Front Vet Sci. 2020;7:583342. doi:10.3389/fvets.2020.583342
25. Hu H z., Granger N, Jeffery N d. Pathophysiology, clinical importance, and management of neurogenic lower urinary tract dysfunction caused by suprasacral spinal cord injury. J Vet Intern Med. 2016;30(5):1575-1588. doi:10.1111/jvim.14557
26. Gill SS, Barstad RD. A review of the surgical management of perineal hernias in dogs. JAAHA. 2018;54(4):179-187. doi:10.5326/JAAHA-MS-6490
27. Grand JG, Bureau S, Monnet E. Effects of urinary bladder retroflexion and surgical technique on postoperative complication rates and long-term outcome in dogs with perineal hernia: 41 cases (2002–2009). JAVMA. 2013;243(10):1442-1447. doi:10.2460/javma.243.10.1442
28. Benzimra C, Decôme M, Maurey C, et al. Intermittent urethral obstruction secondary to caudal sliding of a pelvic bladder in 3 dogs. Can Vet J. 2020;61(3):267-273.
29. Haagsman AN, Kummeling A, Moes ME, Mesu SJ, Kirpensteijn J. Comparison of terazosin and prazosin for treatment of vesico-urethral reflex dyssynergia in dogs. Vet Rec. 2013;173(2):41-41. doi:10.1136/vr.101326
30. Espiñeira MMD, Viehoff FW, Nickel RF. Idiopathic detrusor-urethral dyssynergia in dogs: a retrospective analysis of 22 cases. J Small Anim Pract. 1998;39(6):264-270. doi:10.1111/j.1748-5827.1998.tb03648.x
31. Stilwell C, Bazelle J, Walker D, Stanzani G, Florey J. Detrusor urethral dyssynergy in dogs: 35 cases (2007-2019). J Small Anim Pract. 2021;62(6):468-477. doi:10.1111/jsap.13286
32. Lulich JP, Berent AC, Adams LG, Westropp JL, Bartges JW, Osborne CA. ACVIM small animal consensus recommendations on the treatment and prevention of uroliths in dogs and cats. J Vet Intern Med. 2016;30(5):1564-1574. doi:10.1111/jvim.14559
CE Quiz
This article has been submitted for RACE approval for 1 hour of continuing education credit and will be opened for enrollment upon approval. To receive credit, take the test at vetfolio.com. Free registration is required. Questions and answers online may differ from those below. Tests are valid for 2 years from the date of approval.
1. α-Adrenergic blockers are used to decrease urethral tone and improve emptying in dogs with certain voiding disorders. Which of the following drugs is an α-adrenergic blocker?
a. Prazosin
b. Finasteride
c. Phenylpropanolamine
d. Bethanechol
2. Adverse effects associated with estrogen administration include:
a. Truncal alopecia and pigmentation
b. Tachycardia and syncope
c. Hypertension and proteinuria
d. Vulval swelling and mammary hyperplasia
3. Adverse effects associated with administration of phenylpropanolamine include:
a. Hypertension
b. Vulval swelling
c. Mammary hyperplasia
d. Somnolence
4. Urethral bulking agents may be an effective option for dogs with incontinence due to:
a. Urethral carcinoma
b. Unilateral ureteral ectopia
c. Urethral sphincter mechanism incompetence
d. Functional urethral obstruction
5. Dogs with functional urethral obstruction routinely present with which of the following clinical signs?
a. A narrowed and erratic urine stream
b. Frequent attempts to urinate despite an essentially empty bladder
c. Constant dribbling of urine
d. Persistent dribbling of urine and involuntary voiding of fecal material


















